NetworkNewsBreaks – Arcus Biosciences, Inc. (NYSE: RCUS) Featured in Mizuho Securities Research Report
Arcus Biosciences (NYSE: RCUS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “RCUS is trading up >20% today, which we believe is a result of the focus on TIGIT coming from RHHBY's (not covered) analyst meeting yesterday which highlighted the advancement of tiragolimab into Phase III (SKYSCRAPER-02) and discussion of its role as a novel immune checkpoint. RCUS is developing an anti-TIGIT mAb, AB154, which is currently in Phase II clinical studies, and we expect data disclosure in 4Q20 from this program. Our recent ‘Top of Mind’ note for RCUS…







